Skip to content

奥普科健康

US · OPK #3224 按市值排名
1.53 -0.08 -4.97%
实时 - 追踪5344个代码 - 心跳于52秒前 · 2026-10-16 19:58

估值 各估值倍数与自身5年区间的对比

市净率 0.88 高于历史水平 第68百分位
5年平均 0.87 · 在Diagnostics & Research中排名第2/40
市盈率 -19.86 低于历史水平 第14百分位
5年平均 -7.16 · 前瞻 -5.43
市销率 1.76 高于历史水平 第91百分位
5年平均 1.37 · 前瞻 1.83 · 在Diagnostics & Research中排名第10/43

同业对比 Diagnostics & Research

公司 市值 市盈率(TTM) 市净率 股息率
奥普科健康 (OPK) 1.14B -21.86 0.96 0.00%
Thermo Fisher Scientific (TMO) 255.13B 37.14 4.84 0.26%
Danaher (DHR) 161.01B 40.68 3.06 0.63%
Natera (NTRA) 56.71B -291.44 31.13 0.00%
Agilent Technologies (A) 48.77B 34.12 6.62 0.59%
IDEXX Laboratories Inc (IDXX) 44.15B 39.38 27.38 0.00%

StockVane 追踪范围内同行业的其他公司。

Morningstar

★★★★☆ 合理价值2.17 经济护城河None 不确定性High

当前股价低于晨星合理价值估算42.1%。

合理价值

OPKO Health Inc earns a 4-star quantitative star rating, reflecting our opinion that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 36% discount to our quantitative fair value estimate of $2.17 per share; however, caution is warranted due to this estimate's high uncertainty rating.

The company's valuation metrics bolster our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 101.8% sits in the top 30% compared with global peers. The market price is low relative to the book (accounting) value of the company's equity, which contributes to our view that shares are undervalued.

Conversely, the firm's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of -13.9%, a core component of profitability, ranks in the bottom 20% globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.

经济护城河

The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

作者:Quantitative Equity Report

报价时间 2026-10-16 19:58:57 · 仅供参考,不构成投资建议,也未考虑您的具体情况。

奥普科健康 讨论区 0 条评论

发表评论